drugset / Trial / NCT04200066

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

NCT04200066

Phase 1 Withdrawn University of Rochester
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.

Timeline

Start
2022-06-01
Primary completion
2023-10-01
Completion
2024-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Maprotiline Small molecule Oral
Subject Tamoxifen Small molecule Oral
Subject Temozolomide Small molecule Oral